Deutsche Bank AG Buys 58,687 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Deutsche Bank AG increased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 12.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 519,217 shares of the biotechnology company's stock after acquiring an additional 58,687 shares during the period. Deutsche Bank AG owned about 0.25% of BioCryst Pharmaceuticals worth $3,905,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Xponance Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 9.1% during the fourth quarter. Xponance Inc. now owns 14,896 shares of the biotechnology company's stock worth $112,000 after acquiring an additional 1,242 shares during the period. Sei Investments Co. raised its holdings in shares of BioCryst Pharmaceuticals by 2.8% during the fourth quarter. Sei Investments Co. now owns 57,190 shares of the biotechnology company's stock worth $430,000 after acquiring an additional 1,537 shares during the period. Mariner LLC raised its holdings in shares of BioCryst Pharmaceuticals by 32.1% during the fourth quarter. Mariner LLC now owns 13,258 shares of the biotechnology company's stock worth $100,000 after acquiring an additional 3,224 shares during the period. Arizona State Retirement System raised its holdings in shares of BioCryst Pharmaceuticals by 6.6% during the fourth quarter. Arizona State Retirement System now owns 57,001 shares of the biotechnology company's stock worth $429,000 after acquiring an additional 3,518 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of BioCryst Pharmaceuticals by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 43,920 shares of the biotechnology company's stock worth $330,000 after acquiring an additional 4,129 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on BCRX shares. Barclays raised their price objective on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. Royal Bank of Canada reiterated an "outperform" rating and issued a $13.00 price target (up from $11.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. Needham & Company LLC lifted their price target on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. JPMorgan Chase & Co. lifted their price target on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a research note on Tuesday, May 6th. Finally, Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, BioCryst Pharmaceuticals has a consensus rating of "Buy" and a consensus price target of $16.56.

BioCryst Pharmaceuticals Trading Up 1.9%

Shares of BCRX traded up $0.20 during midday trading on Friday, reaching $10.59. The stock had a trading volume of 3,608,168 shares, compared to its average volume of 3,026,377. The firm has a 50 day simple moving average of $8.38 and a 200-day simple moving average of $8.05. BioCryst Pharmaceuticals, Inc. has a one year low of $5.92 and a one year high of $11.11. The firm has a market cap of $2.22 billion, a PE ratio of -17.36 and a beta of 1.08.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. During the same period in the previous year, the business posted $0.28 earnings per share. BioCryst Pharmaceuticals's revenue for the quarter was up 40.8% on a year-over-year basis. As a group, research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.